Huiyu Pharmaceuticals: Nifedipine Hydrochloride Injection received drug registration certificate.

Huayu Pharmaceuticals announced that the company has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for the company's product, Nifedipine Hydrochloride Injection. The drug is classified as a Class 4 chemical drug, and approval is equivalent to passing the evaluation of generic drug quality and efficacy consistency. Nifedipine Hydrochloride Injection is used clinically for the emergency treatment of abnormally high blood pressure during surgery and hypertensive emergencies. According to data from the MiNai website, the sales of Nifedipine Hydrochloride Injection in urban public hospitals in China in the first half of 2025 are approximately 3.06 billion yuan. The company has carried out preparatory work for the launch and sales of the product, but the ability to generate significant revenue in the future is uncertain. The acquisition of the product registration approval will not have a significant impact on the company's operating performance in the short term.